Stockscreener 앱 받기
1.52
7.88%
-0.13
시간 외 거래:
1.59
0.07
+4.61%
Lexicon Pharmaceuticals Inc 주식(LXRX)의 최신 뉴스
Cantor sets USD 8.00 target for Lexicon Pharmaceuticals stock - ad-hoc-news.de
Lexicon Pharmaceuticals (LXRX) Short Interest & Short Float | Updated Oct 2026 $LXRX - MarketBeat
Lexicon Pharmaceuticals stock faces a Q2 loss as trials advance - AD HOC NEWS
Lexicon Pharmaceuticals, Inc.Common Stock (Nasdaq:LXRX) Stock Quote - FinancialContent
Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript - Benzinga
Lexicon Pharmaceuticals Q2 2026 Earnings Call: Complete Transcript - Benzinga
Fair value rises to USD 4.55 for Lexicon Pharmaceuticals stock - AD HOC NEWS
Lexicon Pharmaceuticals, Inc. (LXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Lexicon Pharmaceuticals (LXRX) Stock Fair Value Rises After SONATA HCM Trial Progress - Yahoo Finance
Cantor Fitzgerald targets Lexicon Pharmaceuticals stock at USD 8.00 - AD HOC NEWS
Lexicon Pharmaceuticals upgraded to Buy with ke... - Pluang
Lexicon Pharmaceuticals: Upgrading On Sotagliflozin HCM Data In Q1 '27 And More - Seeking Alpha
Analyst Bullish on Lexicon Pharmaceuticals' Prospects - Intellectia AI
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today - Yahoo Finance
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today - The Motley Fool
Cantor Fitzgerald Initiates Overweight on Lexicon Pharmaceuticals (LXRX) Ahead of Phase 3 Inpefa Data - GuruFocus
Lexicon a new overweight at Cantor on optimism for Inpefa in cardiomyopathy - Seeking Alpha
Why is Lexicon Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM - Investing.com
This Lexicon Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
LXRX Initiated Coverage by Cantor Fitzgerald -- Rating Set at Ov - GuruFocus
Cantor Fitzgerald initiates coverage of Lexicon Pharmaceuticals with Overweight rating, $8 price target - TradingView
Lexicon Pharmaceuticals (NasdaqCM:LXRX) Stock Forecast & Analyst Predictions - Simply Wall Street
Lexicon Pharmaceuticals Shares Rise After Cantor Fitzgerald Initiates With Overweight Rating - Yahoo Finance
Lexicon Pharmaceuticals surges as Cantor Fitzgerald sees unencumbered path in HCM - Yahoo Finance
Lexicon Pharmaceuticals stock trades near its yearly low - AD HOC NEWS
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data - finance.yahoo.com
Lexicon Pharmaceuticals at cantorfitzgerald healthcare conference: focus sharpens - Investing.com
Lexicon Pharmaceuticals at cantorfitzgerald healthcare conference: focus sharpens By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset By Investing.com - Investing.com Canada
Lexicon Pharmaceuticals at Citi summit: hcm data, t1d reset By Investing.com - Investing.com UK
Heart Failure Trial Data Might Change The Case For Investing In Lexicon Pharmaceuticals (LXRX) - webull.com
Heart Failure Trial Data Might Change The Case For Investing In Lexicon Pharmaceuticals (LXRX) - simplywall.st
Lexicon Pharmaceuticals Stock Price Forecast. Should You Buy LXRX? - StockInvest.us
Here's Why You Should Add LXRX Stock to Your Portfolio Now - Eastern Progress
Lexicon Pharmaceuticals Inc (LXRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Three New York investor conferences will hear from Lexicon - Stock Titan
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences - finance.yahoo.com
Lexicon Pharmaceuticals (LXRX) Posts Positive Heart Failure Tria - GuruFocus
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure - Yahoo Finance
Sotagliflozin Linked to Fewer Heart-Failure Events in Patients With BP as Low as 100 - Stock Titan
Lexicon Pharmaceuticals Inc. (LXRX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Lexicon (LXRX) Results at a Glance: EPS Misses Its Estimate in the Reported Period; Post-Earnings: The Market Price Advances 0.87% at the CloseNegative Surprise Momentum - vinanet.vn
Lexicon Pharma Earns $10 Million Milestone Payment from Novo Nordisk - marketscreener.com
Lexicon Pharmaceuticals (LXRX) Advances Obesity Drug Trial, Faces Valuation Challenges - GuruFocus
Lexicon Pharmaceuticals Gets $10 Million Novo Nordisk Milestone Payment for LX9851 - marketscreener.com
LXRX Stock Edges Higher On $10M Payout From Novo Nordisk — Retail Traders Highlight More Cash Milestones On The Horizon - Yahoo Finance
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851 - finance.yahoo.com
The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift - simplywall.st
The Bull Case For Lexicon Pharmaceuticals (LXRX) Could Change Following Steep Q2 Revenue Drop And Loss Shift - simplywall.st
8.28%
자본화:
|
볼륨(24시간):